Insider Selling: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Sells $761,217.50 in Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Michael Parini sold 4,250 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Friday, July 5th. The stock was sold at an average price of $179.11, for a total transaction of $761,217.50. Following the completion of the transaction, the executive vice president now directly owns 39,253 shares in the company, valued at approximately $7,030,604.83. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Michael Parini also recently made the following trade(s):

  • On Friday, May 3rd, Michael Parini sold 1,622 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $172.06, for a total transaction of $279,081.32.

Vertex Pharmaceuticals stock opened at $176.01 on Friday. The stock has a 50 day moving average price of $175.38. The stock has a market capitalization of $45.78 billion, a P/E ratio of 62.19, a P/E/G ratio of 2.59 and a beta of 1.43. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.66 and a current ratio of 3.78. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $151.80 and a fifty-two week high of $195.81.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Tuesday, April 30th. The pharmaceutical company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.49. The business had revenue of $857.00 million for the quarter, compared to the consensus estimate of $853.00 million. Vertex Pharmaceuticals had a net margin of 66.01% and a return on equity of 22.63%. The firm’s quarterly revenue was up 34.3% compared to the same quarter last year. During the same period last year, the firm posted $0.76 earnings per share. As a group, research analysts predict that Vertex Pharmaceuticals Incorporated will post 3.06 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the company. FMR LLC grew its position in Vertex Pharmaceuticals by 19.3% during the first quarter. FMR LLC now owns 24,434,159 shares of the pharmaceutical company’s stock valued at $4,494,663,000 after purchasing an additional 3,951,050 shares in the last quarter. Norges Bank purchased a new position in Vertex Pharmaceuticals during the fourth quarter valued at approximately $380,584,000. BlackRock Inc. grew its position in Vertex Pharmaceuticals by 2.9% during the first quarter. BlackRock Inc. now owns 20,176,298 shares of the pharmaceutical company’s stock valued at $3,711,428,000 after purchasing an additional 568,488 shares in the last quarter. GQG Partners LLC purchased a new position in Vertex Pharmaceuticals during the first quarter valued at approximately $94,444,000. Finally, Marshall Wace North America L.P. grew its position in Vertex Pharmaceuticals by 58.4% during the first quarter. Marshall Wace North America L.P. now owns 792,007 shares of the pharmaceutical company’s stock valued at $145,690,000 after purchasing an additional 291,952 shares in the last quarter. 94.94% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts have recently issued reports on the stock. Goldman Sachs Group raised shares of Lenovo Group from a “neutral” rating to a “buy” rating in a research note on Thursday, May 23rd. They noted that the move was a valuation call. BidaskClub cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Leerink Swann cut shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $185.40 price objective on the stock. in a research note on Tuesday, March 19th. They noted that the move was a valuation call. William Blair reaffirmed a “market perform” rating on shares of aTyr Pharma in a research note on Tuesday, March 26th. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of BioMarin Pharmaceutical in a research note on Sunday, June 2nd. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and seventeen have given a buy rating to the stock. Vertex Pharmaceuticals has an average rating of “Buy” and a consensus target price of $204.36.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.

See Also: Derivative

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.